VICTOR
NAVAS LOPEZ
Hospital Infantil Universitario Niño Jesus de Madrid
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Infantil Universitario Niño Jesus de Madrid (19)
2024
-
Blood gene expression biomarkers of response to anti-TNF drugs in pediatric inflammatory bowel diseases before initiation of treatment
Biomedicine and Pharmacotherapy, Vol. 173
2023
-
Association between HLA DNA Variants and Long-Term Response to Anti-TNF Drugs in a Spanish Pediatric Inflammatory Bowel Disease Cohort
International Journal of Molecular Sciences, Vol. 24, Núm. 2
-
Benefits of Paediatric to Adult Transition Programme in Inflammatory Bowel Disease: The BUTTERFLY Study of GETECCU and SEGHNP
Journal of Clinical Medicine, Vol. 12, Núm. 14
-
Comments on: Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children
Pharmacological Research
-
Microbial and immune faecal determinants in infants hospitalized with COVID-19 reflect bifidobacterial dysbiosis and immature intestinal immunity
European Journal of Pediatrics, Vol. 182, Núm. 10, pp. 4633-4645
-
Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children
Pharmacological Research, Vol. 194
2022
-
Safety and Potential Efficacy of Escalating Dose of Ustekinumab in Pediatric Crohn Disease (the Speed-up Study): A Multicenter Study from the Pediatric IBD Porto Group of ESPGHAN
Journal of Pediatric Gastroenterology and Nutrition, Vol. 75, Núm. 6, pp. 717-723
2021
-
Correction to: Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicenter Spanish study (European Journal of Pediatrics, (2021), 180, 9, (3029-3038), 10.1007/s00431-021-04063-6)
European Journal of Pediatrics
-
Pharmacogenetics of trough serum anti-TNF levels in paediatric inflammatory bowel disease
British Journal of Clinical Pharmacology, Vol. 87, Núm. 2, pp. 447-457
-
Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study
European Journal of Pediatrics, Vol. 180, Núm. 9, pp. 3029-3038
-
Whole transcription profile of responders to anti-tnf drugs in pediatric inflammatory bowel disease
Pharmaceutics, Vol. 13, Núm. 1, pp. 1-17
2020
-
Gene signatures of early response to anti-TNF drugs in pediatric inflammatory bowel disease
International Journal of Molecular Sciences, Vol. 21, Núm. 9
-
Genetic Predictors of Long-term Response to Antitumor Necrosis Factor Agents in Pediatric Inflammatory Bowel Disease
Journal of pediatric gastroenterology and nutrition, Vol. 71, Núm. 4, pp. 508-515
-
Predictors of response to exclusive enteral nutrition in newly diagnosed crohn’s disease in children: PRESENCE Study from SEGHNP
Nutrients, Vol. 12, Núm. 4
2015
-
Commercial enteral formulas and nutritional support team
Diet and Nutrition in Critical Care (Springer New York), pp. 1203-1219
2014
-
The complete picture of changing pediatric inflammatory bowel disease incidence in Spain in 25years (1985-2009): The EXPERIENCE registry
Journal of Crohn's and Colitis, Vol. 8, Núm. 8, pp. 763-769
2013
-
Analysis of the Spanish national registry for pediatric home enteral nutrition (NEPAD): Implementation rates and observed trends during the past 8 years
European Journal of Clinical Nutrition, Vol. 67, Núm. 4, pp. 318-323
2011
-
Consensus on paediatric enteral nutrition access: A document approved by SENPE/SEGHNP/ANECIPN/SECP
Nutricion Hospitalaria, Vol. 26, Núm. 1, pp. 1-15
2010
-
Home parenteral nutritrion in children: Procedures, experiences and reflections
Nutricion Hospitalaria, Vol. 25, Núm. 5, pp. 705-711